DK1592449T3 - Sensibilisering af celler til apoptose ved selektiv blokade af cytokiner - Google Patents

Sensibilisering af celler til apoptose ved selektiv blokade af cytokiner

Info

Publication number
DK1592449T3
DK1592449T3 DK04709222T DK04709222T DK1592449T3 DK 1592449 T3 DK1592449 T3 DK 1592449T3 DK 04709222 T DK04709222 T DK 04709222T DK 04709222 T DK04709222 T DK 04709222T DK 1592449 T3 DK1592449 T3 DK 1592449T3
Authority
DK
Denmark
Prior art keywords
cells
cytokine
apoptosis
sensitization
cytokines
Prior art date
Application number
DK04709222T
Other languages
Danish (da)
English (en)
Inventor
Giorgio Dr Stassi
Matilde Dr Todaro
Original Assignee
Giorgio Dr Stassi
Matilde Dr Todaro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giorgio Dr Stassi, Matilde Dr Todaro filed Critical Giorgio Dr Stassi
Application granted granted Critical
Publication of DK1592449T3 publication Critical patent/DK1592449T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04709222T 2003-02-07 2004-02-09 Sensibilisering af celler til apoptose ved selektiv blokade af cytokiner DK1592449T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03002603A EP1444989A1 (fr) 2003-02-07 2003-02-07 Sensibilisation de cellules à l'apoptose par bloquage selective de cytokines
PCT/EP2004/001177 WO2004069274A2 (fr) 2003-02-07 2004-02-09 Sensibilisation des cellules pour l'apoptose par blocage selectif de cytokines

Publications (1)

Publication Number Publication Date
DK1592449T3 true DK1592449T3 (da) 2008-09-29

Family

ID=32605342

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04709222T DK1592449T3 (da) 2003-02-07 2004-02-09 Sensibilisering af celler til apoptose ved selektiv blokade af cytokiner

Country Status (10)

Country Link
US (2) US7645449B2 (fr)
EP (3) EP1444989A1 (fr)
JP (1) JP2006519190A (fr)
AT (1) ATE396741T1 (fr)
AU (1) AU2004210432B2 (fr)
CA (1) CA2515302A1 (fr)
DE (1) DE602004014103D1 (fr)
DK (1) DK1592449T3 (fr)
ES (1) ES2303630T3 (fr)
WO (1) WO2004069274A2 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
ATE492563T1 (de) 2004-11-17 2011-01-15 Amgen Inc Vollständige humane monoklonale antikörper gegen il-13
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
GB0600903D0 (en) * 2006-01-17 2006-02-22 Cancer Rec Tech Ltd Treatment of cancer
CA2646626A1 (fr) * 2006-03-22 2007-09-27 Apogenix Gmbh Anticorps specifique de l'il-4 humaine pour le traitement du cancer
RU2009101783A (ru) * 2006-06-21 2010-07-27 Апогеникс Гмбх (De) Дифференциальная экспрессия цитокинов il-4 и/или il-10 в злокачественной опухоли человека
WO2008003514A2 (fr) * 2006-07-06 2008-01-10 Apogenix Gmbh Mutéines d'il-4 humaines dans une thérapie contre le cancer
BRPI0715115A2 (pt) * 2006-08-03 2013-06-04 Vaccinex Inc anticorpo monoclonal isolado, molÉcula de Ácido nucleico isolada, vetor de expressço, cÉlula hospedeira, mÉtodos para tratar uma doenÇa, e para produzir um anticorpo monoclonal isolado, uso do anticorpo monoclonal isolado, e, composiÇço farmacÊutica
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
SG177924A1 (en) * 2006-12-22 2012-02-28 Genentech Inc Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders
US7618992B2 (en) 2006-12-29 2009-11-17 Astellas Pharma Inc. Method of treating cancer by co-administration of anticancer agents
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CN102124336A (zh) * 2008-06-12 2011-07-13 健泰科生物技术公司 用于筛选抑制神经变性的化合物的方法
US8183297B2 (en) * 2008-07-11 2012-05-22 Taipei Veterans General Hospital Medium and device for proliferation of stem cells and treatment of cancer-related stem cell with resveratrol
CN101353339B (zh) * 2008-09-16 2012-06-27 郑州大学 槲皮素铂的合成
US20110171219A1 (en) * 2008-09-19 2011-07-14 Fahar Merchant Treating cancer stem cells using targeted cargo proteins
WO2010036702A1 (fr) 2008-09-25 2010-04-01 Cephalon, Inc. Formulations liquides de bendamustine
WO2010062904A2 (fr) 2008-11-25 2010-06-03 Biogen Idec Ma Inc. Utilisation d'antagonistes dr6 et p75 pour favoriser la survie de cellules du systeme nerveux
JP2012515210A (ja) 2009-01-15 2012-07-05 セファロン、インク． ベンダムスチン遊離塩基の新規の形態
AR078986A1 (es) * 2009-11-12 2011-12-14 Genentech Inc Un metodo para promover la densidad de espinas dendriticas
WO2012097160A1 (fr) * 2011-01-14 2012-07-19 Nexmed Holdings, Inc. Méthode d'administration rectale pour des peptides thérapeutiques
JP6395379B2 (ja) 2011-01-18 2018-09-26 バイオニズ リミテッド ライアビリティー カンパニー γｃサイトカイン活性を調節するための組成物および方法
WO2013029011A2 (fr) 2011-08-25 2013-02-28 University Of Central Florida Research Foundation, Inc. Procédés et compositions renfermant un peptide dérivé de l'extrémité c terminale de bax
US9403888B2 (en) 2011-12-09 2016-08-02 University Of Central Florida Research Foundation, Inc. Compositions and methods for purifying Bax
EP2825191B1 (fr) 2012-03-16 2019-08-28 University Health Network Protéine toso soluble et son utilisation dans le traitement des maladies auto-immunes
EP3016982A4 (fr) 2013-07-03 2017-02-22 University Health Network Anticorps anti-toso
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
CA2962062A1 (fr) 2014-07-18 2016-01-21 University Of Central Florida Research Foundation, Inc. Procedes et compositions comprenant un peptide ct20
KR102654684B1 (ko) 2015-10-09 2024-04-04 바이오니즈 테라퓨틱스, 아이엔씨. 감마-ｃ-사이토카인 활성의 조정
CA3001139A1 (fr) 2015-10-23 2017-04-27 The Trustees Of Columbia University In The City Of New York Reticulation du collagene induite par laser dans le tissu
US11497403B2 (en) 2016-06-10 2022-11-15 The Trustees Of Columbia University In The City Of New York Devices, methods, and systems for detection of collagen tissue features
CN106727115B (zh) * 2016-12-13 2019-08-13 广东科玮生物技术股份有限公司 一种用于增生性疤痕修复的护肤霜及其制备方法
US11666481B1 (en) 2017-12-01 2023-06-06 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of collagen-containing tissues
CN111208283B (zh) * 2018-11-21 2023-09-26 中国科学院分子细胞科学卓越创新中心 增效的肿瘤抑制组合物及其应用
WO2023092463A1 (fr) * 2021-11-26 2023-06-01 中国科学院深圳先进技术研究院 Application de chlorhydrate de doxorubicine dans inhibition de mcl-1

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US645449A (en) * 1899-04-05 1900-03-13 Charles Blume Brow-band-attaching device.
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
US6534051B1 (en) * 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
WO1996001318A1 (fr) 1994-07-05 1996-01-18 Steeno Research Group A/S Immunomodulateurs
CA2196200A1 (fr) 1994-07-29 1996-02-15 Michael Joseph Browne Nouveaux composes
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
CA2250164C (fr) 1996-04-05 2011-12-06 South Alabama Medical Science Foundation Reponse immunitaire mediee par des lymphocytes t specifiques de l'antigene oncofoetal : manipulation et utilisations de cytotoxiques cd4, cd8 specifiques de l'antigene oncofoetal et de lymphocytes t suppresseurs et de l'interleukin-10
US20030124125A1 (en) 1996-04-05 2003-07-03 South Alabama Medical Science Foundation Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
AU5221998A (en) 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
EP1089764B1 (fr) 1998-06-10 2004-09-01 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Stimulation du systeme immunitaire
WO2000004901A1 (fr) * 1998-07-21 2000-02-03 Thomas Jefferson University Petites molecules inhibitrices de proteines bcl-2
ATE342976T1 (de) 1998-12-14 2006-11-15 Genetics Inst Llc Cytokinrezeptor-kette
CA2362264C (fr) * 1999-02-08 2012-05-08 Medvet Science Pty. Ltd. Domaine de fixation a la cytokine
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
CA2404365A1 (fr) 2000-03-31 2001-10-11 Idec Pharmaceutical Corporation Utilisation combinee d'anticorps ou d'antagonistes anti-cytokine et d'anti-cd20 pour le traitement du lymphome b
US20020076409A1 (en) * 2000-07-12 2002-06-20 March Carl J. Method for treating cancer
CA2447360A1 (fr) 2001-05-09 2002-11-14 Alk-Abello A/S Compositions pharmaceutiques destines a prevenir ou traiter les maladies associees aux cellules th1 et th2 par modulation du rapport th1/th2
EP1578912A4 (fr) * 2001-10-26 2007-12-26 Centocor Inc Proteines muteines il-13, anticorps, compositions, procedes et utilisations
US20040023338A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
EP1507548B1 (fr) 2002-05-27 2014-10-01 CanImGuide Therapeutics AB Procede de determination de composes affectant le systeme immunitaire
EP1808200A3 (fr) 2002-10-11 2007-09-19 Sentoclone AB Immunothérapie pour cancer
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
ATE492563T1 (de) * 2004-11-17 2011-01-15 Amgen Inc Vollständige humane monoklonale antikörper gegen il-13
US20070122855A1 (en) * 2005-11-28 2007-05-31 Targetgen Inc. Methods for diagnosing hepatocellular carcinoma

Also Published As

Publication number Publication date
WO2004069274A3 (fr) 2004-11-11
EP1444989A1 (fr) 2004-08-11
EP1592449A2 (fr) 2005-11-09
WO2004069274A2 (fr) 2004-08-19
ES2303630T3 (es) 2008-08-16
EP1592449B1 (fr) 2008-05-28
EP2075008A3 (fr) 2009-12-02
JP2006519190A (ja) 2006-08-24
AU2004210432B2 (en) 2008-12-18
EP2075008A2 (fr) 2009-07-01
US20060257401A1 (en) 2006-11-16
AU2004210432A1 (en) 2004-08-19
CA2515302A1 (fr) 2004-08-19
ATE396741T1 (de) 2008-06-15
US20100099742A1 (en) 2010-04-22
DE602004014103D1 (de) 2008-07-10
US7645449B2 (en) 2010-01-12

Similar Documents

Publication Publication Date Title
DK1592449T3 (da) Sensibilisering af celler til apoptose ved selektiv blokade af cytokiner
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
DE602004028934D1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
GT200600407A (es) Compuestos ppar activos
DE60325761D1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
ATE521598T1 (de) 5-phenylthiazol-derivate und ihre verwendung als pi3 kinase inhibitoren
WO2006137934A3 (fr) Eloignement volontaire de cellules migratoires humaines d'une source d'agents
NO20043536L (no) Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister
ATE308323T1 (de) Diaminothiazole und ihre anwendung als cdk4 inhibitoren
ATE343582T1 (de) Derivate von (6, 7-dihydro -5h-imidazo(1,2 - a)imidazol -3 -sulfonylamino)-propionamid und deren verwendung als inhibitoren der interaktion von cams und leukointreginen
ATE258553T1 (de) Phenyl-substituierte indolizinderivate und deren verwendung als histamin h3 liganden
NO20053598D0 (no) Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister.
ATE425962T1 (de) Peptid-deformylase-hemmer
ATE372342T1 (de) Substituierte aminoisoxazolinderivate und ihre verwendung als antidepressiva
ECSP045213A (es) Aminas de fenilpirimidina como inhibidores ige
DE50211897D1 (de) 3H-NAPHTHOÄ2,1-bÜ-PYRAN-DERIVATE SOWIE DEREN VERWENDUNG
IS7441A (is) Peptíðdeformýlasatálmar
FR2845827B1 (fr) Plateforme radiotelephonique demontable
ATE382062T1 (de) Antikörper gegen allgegenwärtige mitochondriale kreatinkinase und dessen verwendung
ES1051284Y (es) Escalera para obras y construcciones.
MX278306B (es) Silanos funcionales con epoxi, metodos para la produccion de los mismos y uso del mismo.
ES1054583Y (es) Electrodos para arsonvalizacion.
ES1055361Y (es) Mesa elevadora autorregulable
ES1051852Y (es) Soporte para pastillas bactericidas utilizadas en urinarios.
ES1051597Y (es) Plataforma colgante perfeccionada para andamios.